| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Diacetone-D-mannitol does not bind to a specific biological target. As a synthetic intermediate, it is chemically manipulated to create active compounds, such as the beta-blocker Nebivolol, where it serves as a precursor. It may also act as a chiral selector, but this is a chemical interaction, not a pharmacological one. It is not intended to act on a receptor or enzyme in the body.
|
|---|---|
| ln Vitro |
The compound shows no intrinsic pharmacological activity in vitro. As a protected sugar alcohol, it is inert in biological assays. Its role is purely as a chemical intermediate or an excipient. It is not an enzyme inhibitor, receptor agonist, or cytotoxic agent in the typical pharmacological screening panels. Its value lies in its unique chemical structure used for building chirality into other molecules.
|
| ln Vivo |
In vivo, Diacetone-D-mannitol has no direct therapeutic activity. It is an intermediate used in the synthesis of other drugs. As a formulation protective agent, it is inert and serves as an excipient. The final drug products synthesized from it (e.e., Nebivolol) have in vivo activity (e.g., antihypertensive effects), but the intermediate does not. No research exists on its direct in vivo efficacy.
|
| Enzyme Assay |
Cell‑free assays for Diacetone-D-mannitol are chemical, not biological. Standard analytical protocols include TLC and HPLC with UV detection to verify the purity (>98%) and identity of the compound. For quality control, the specific optical rotation is measured using a polarimeter. These protocols ensure the intermediate meets the required standards for subsequent pharmaceutical synthesis.
|
| Cell Assay |
There are no standard cell-based assays for Diacetone-D-mannitol. It is not used to treat cells. It is a protected sugar that is not taken up by cells or processed effectively. Its use is restricted to the chemistry laboratory. Researchers will deprotect it to free mannitol if a biological effect is needed, or more likely, they will use it to synthesize a complex drug that will be tested later.
|
| Animal Protocol |
Animal experiments are not performed on Diacetone-D-mannitol as a drug candidate. Its role is to serve as a precursor for the synthesis of drugs that are eventually tested in animals. For example, to test the pharmacokinetics of a novel compound, the compound is synthesized using intermediates like Diacetone-D-mannitol. No protocols exist for this intermediate alone.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data is available for Diacetone-D-mannitol as it is not a drug. If ingested, it is a chemical reagent. The isopropylidene protecting groups would likely be metabolized in the liver, but no studies confirm this. The compound is a solid stored at room temperature. It is used in research settings, not for in vivo administration.
|
| Toxicity/Toxicokinetics |
As a laboratory chemical, Diacetone-D-mannitol is generally considered non-toxic. It should be handled with standard precautions (gloves and safety glasses). Specific toxicological data such as LD50, carcinogenicity, or mutagenicity is not available due to its status as a synthetic intermediate. It is not intended for human consumption.
|
| Additional Infomation |
Diacetone-D-mannitol is an advanced research chemical, not an approved drug. It is specifically used in the synthesis of the antihypertensive drug Nebivolol. It is also used in the preparation of chiral auxiliaries and building blocks for organic chemistry. The molecular formula is C12H22O₆, with a molecular weight of 262.30 g/mol. The purity is typically 97%.
|
| Molecular Formula |
C12H22O6
|
|---|---|
| Molecular Weight |
262.3
|
| Exact Mass |
262.142
|
| CAS # |
1707-77-3
|
| PubChem CID |
96011
|
| Appearance |
Solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
382.0±32.0 °C at 760 mmHg
|
| Melting Point |
120-122 °C(lit.)
|
| Flash Point |
184.8±25.1 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.476
|
| LogP |
0.61
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
273
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC1(OC[C@@H](O1)[C@H]([C@@H]([C@H]2COC(O2)(C)C)O)O)C
|
| InChi Key |
ODYBCPSCYHAGHA-ZYUZMQFOSA-N
|
| InChi Code |
InChI=1S/C12H22O6/c1-11(2)15-5-7(17-11)9(13)10(14)8-6-16-12(3,4)18-8/h7-10,13-14H,5-6H2,1-4H3/t7-,8-,9-,10-/m1/s1
|
| Chemical Name |
(1S,2S)-1,2-bis[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]ethane-1,2-diol
|
| Synonyms |
1,2:5,6-Di-O-isopropylidene-D-mannitol, 97%
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8124 mL | 19.0621 mL | 38.1243 mL | |
| 5 mM | 0.7625 mL | 3.8124 mL | 7.6249 mL | |
| 10 mM | 0.3812 mL | 1.9062 mL | 3.8124 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
